{
    "clinical_study": {
        "@rank": "60424", 
        "arm_group": [
            {
                "arm_group_label": "Imeglimin (Dose 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Imeglimin (Dose 2)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Imeglimin (Dose 3)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Imeglimin (Dose 4)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus\n      placebo. The study will be performed in subjects with type 2 diabetes either naive of\n      treatment or previously treated with an oral monotherapy excluding thiazolidinedione."
        }, 
        "brief_title": "A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has given written informed consent\n\n          2. Male and female type 2 diabetic subjects, either na\u00efve of antidiabetic agents or\n             treated with an oral anti-diabetic monotherapy.\n\n          3. Body mass index (BMI) : \u2265 24 to \u2264 40 kg/m\u00b2\n\n          4. HbA1c criteria: \u2265 7% and \u2264 9.5%\n\n          5. Creatinine clearance \u2265 50 mL/[min*1.73 m2] at Screening Visit\n\n          6. Effective contraception for women of child bearing potential\n\n        Exclusion Criteria:\n\n          1. Any disease which in the investigator's opinion would exclude the subject from the\n             study\n\n          2. Acute cardiovascular event within 3 months before randomization\n\n          3. Uncontrolled high blood pressure\n\n          4. Impairment of hepatic function\n\n          5. History of drug-induced Torsades de Pointes or a marked baseline prolongation of the\n             QTc interval\n\n          6. Pregnancy or lactation\n\n          7. Use of any non-permitted medication\n\n          8. Positive screen for viral hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951235", 
            "org_study_id": "PXL008-008", 
            "secondary_id": "2012-004045-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Imeglimin (Dose 1)", 
                    "Imeglimin (Dose 2)", 
                    "Imeglimin (Dose 3)", 
                    "Imeglimin (Dose 4)"
                ], 
                "intervention_name": "Imeglimin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "contact": {
                "last_name": "Valdis Pirags"
            }, 
            "facility": {
                "address": {
                    "city": "Riga", 
                    "country": "Latvia"
                }, 
                "name": "Pauls Stradins Clinical University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Latvia"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Mellitus.", 
        "overall_contact": {
            "email": "pascale.fouqueray@poxelpharma.com", 
            "last_name": "Pascale Fouqueray, MD", 
            "phone": "33-6-9801-7103"
        }, 
        "overall_official": {
            "affiliation": "P. Stradins Clinical University Hospital", 
            "last_name": "Valdis Pirags, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "Baseline and week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951235"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to week 24"
        }, 
        "source": "Poxel SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Poxel SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}